Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Gene profiling in early stage disease.

Rachel Midgley¹, Kakil Rasul, Haitham Al Salama

¹Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK.

Cancer Journal (Sudbury, Mass.)

|June 8, 2010

Summary

Adjuvant chemotherapy for stage II colon cancer overtreats many patients. A new multigene assay accurately predicts recurrence risk, potentially identifying patients who will benefit from treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reliable classification of polyps based on artificial intelligence: a development and validation study.

EClinicalMedicine·2026

Same author

Quality of life outcomes in colorectal cancer survivors: insights from an analytical study at a tertiary cancer center-Qatar.

Frontiers in oncology·2026

Same author

Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.

NPJ precision oncology·2026

Same author

Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.

Cell·2025

Same author

Early-stage lung adenocarcinoma affects DNA methylation and gene expression in adjacent tissues.

EMBO reports·2025

Same author

Activin A affects colorectal cancer progression and immunomodulation in a stage dependent manner.

Scientific reports·2025

Area of Science:

Oncology
Molecular Diagnostics
Translational Research

Background:

Adjuvant chemotherapy for colorectal cancer offers limited benefit to many stage II patients, leading to overtreatment and toxicity.
Current molecular diagnostics for predicting chemotherapy response in stage II colon cancer are limited by small sample sizes and variable methodologies.
There is a need for reliable biomarkers to identify patients who will benefit from adjuvant chemotherapy.

Purpose of the Study:

To validate a novel reverse transcriptase polymerase chain reaction (RT-PCR) multigene assay for predicting recurrence risk in stage II colon cancer.
To assess the utility of the multigene assay as a prognostic tool for guiding adjuvant chemotherapy decisions.

Main Methods:

A novel RT-PCR multigene assay was developed and performed on RNA extracted from paraffin-embedded tumor tissue.

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Experiment Videos

Last Updated: Jun 12, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

The assay was validated in a cohort of 1436 patients with stage II colon cancer.

Recurrence risk was analyzed using Cox proportional hazards models.

Main Results:

The multigene assay demonstrated a significant association with recurrence risk in stage II colon cancer patients (HR/25 units = 1.58; 95% CI, 1.15-2.15; P = 0.004).
The assay showed predictive value for identifying patients at higher risk of recurrence.
Conventional histopathological staging remains the primary method, but molecular markers are emerging.

Conclusions:

The validated RT-PCR multigene assay shows promise as a prognostic tool for stage II colon cancer.
This molecular diagnostic tool may help personalize adjuvant chemotherapy decisions, avoiding overtreatment.
Further validation and integration into clinical practice could improve patient outcomes.